2010
DOI: 10.1007/s11904-009-0036-6
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Individuals infected with HIV-1 and nearly everyone vaccinated with HIV-1 vaccines will, in time, generate antibodies against viral proteins. These antibodies do not resolve natural infection, and vaccine candidates that successfully stimulate the production of high titers of neutralizing antibodies have failed to protect against infection. In spite of this, antibodies continue to be a focus of vaccine research. One reason for the continued interest in antibodies is the failure of a vaccine engineered to gener… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

1
28
0
4

Year Published

2013
2013
2024
2024

Publication Types

Select...
7
2

Relationship

1
8

Authors

Journals

citations
Cited by 34 publications
(33 citation statements)
references
References 55 publications
1
28
0
4
Order By: Relevance
“…These measurements are made early after vaccination (hours to days) and in relevant (i.e., lymph nodes) and/or accessible (i.e., peripheral blood) tissue compartments. In contrast, immunogenicity quantifies the magnitude and quality (i.e., breadth and skewing) of antigen-specific humoral (104) and T cell (105) responses and can be measured months to years after vaccination in both peripheral and effector (i.e., mucosal) tissue compartments. The quality of vaccine-induced adaptive immune responses can be further defined by employing multiparameter flow cytometry, transcriptomics, and other technologies to exhaustively characterize purified antigen-specific, vaccine-induced T cells (106) and B cells.…”
Section: Systems Vaccinologymentioning
confidence: 99%
“…These measurements are made early after vaccination (hours to days) and in relevant (i.e., lymph nodes) and/or accessible (i.e., peripheral blood) tissue compartments. In contrast, immunogenicity quantifies the magnitude and quality (i.e., breadth and skewing) of antigen-specific humoral (104) and T cell (105) responses and can be measured months to years after vaccination in both peripheral and effector (i.e., mucosal) tissue compartments. The quality of vaccine-induced adaptive immune responses can be further defined by employing multiparameter flow cytometry, transcriptomics, and other technologies to exhaustively characterize purified antigen-specific, vaccine-induced T cells (106) and B cells.…”
Section: Systems Vaccinologymentioning
confidence: 99%
“…It is important to clarify these findings so that we will know that a vaccine that stimulates the production of ADCC antibodies will protect men and women equally. In the past, several studies have assessed the significance of ADCC antibodies in host defense against HIV-1-infected cells; 14,[29][30][31] however, the purpose of these studies was to determine whether there are differences between men and women in HIV-1 gp120-specific antibody titers responsible for ADCC activity. To accomplish this, we obtained serum samples from asymptomatic HIV-1-infected individuals matched for CD4 + cell number, HIV-1 viral load, age, and ethnicity and evaluated their ADCC activity (Table 1).…”
mentioning
confidence: 99%
“…Possible functions of FIV-specific antibodies, such as the ones described in this study, could include viral neutralization, viral opsonization and/or antibody-dependent cell-mediated cytotoxicity (reviewed in (Tomaras and Haynes, 2009; Baum, 2010)). Given that IgG subclasses have different functional properties and that the presence of human IgG subclasses can vary with HIV disease state (reviewed in (Tomaras and Haynes, 2009)), it would be interesting to compare the kinetics and levels of the three (possibly four) domestic cat IgG subclasses (Grant, 1995b) throughout FIV infection.…”
Section: Discussionmentioning
confidence: 99%